rs610604 — TNFAIP3

TNFAIP3 Intronic Signal — The Psoriasis-Specific Brake Failure

The TNFAIP3 gene at chromosome 6q23.3 encodes A20, the central negative regulator of NF-κB inflammatory signaling. Multiple independent genetic signals cluster at this locus, each tagging different disease susceptibilities and haplotypes — but not all signals confer the same risks. rs610604, an intronic variant sitting inside TNFAIP3 itself (rather than in the upstream intergenic region), marks the primary psoriasis susceptibility haplotype¹¹ primary psoriasis susceptibility haplotype
Nair et al. 2009 identified rs610604 as the most significant TNFAIP3 signal for psoriasis in a genome-wide scan of 1,409 psoriasis cases and 1,436 controls, followed up in 5,048 cases and 5,041 controls at this locus. Critically, this psoriasis haplotype is genetically distinct from the rheumatoid arthritis and lupus signals at the same locus — a finding with direct clinical implications.

The Mechanism

rs610604 sits in intron 6 of TNFAIP3 and does not alter the A20 protein sequence. Its biological effect is regulatory: RegulomeDB annotation²² RegulomeDB annotation
RegulomeDB scores transcription factor binding evidence and chromatin accessibility; score 4 indicates TF binding plus DNase hypersensitivity, consistent with an active regulatory region assigns this variant a score of 4, indicating evidence of transcription factor binding plus open chromatin — the molecular signature of a functional intronic regulatory element. The G allele of rs610604 likely modulates TNFAIP3 expression in keratinocytes or skin-resident immune cells in a tissue-specific manner, in contrast to the upstream regulatory variants rs6920220 and rs10499194 that primarily affect A20 levels in synovial and hematopoietic cells.

A20 functions as a dual ubiquitin-editing enzyme³³ dual ubiquitin-editing enzyme
A20 has both deubiquitinase (OTU domain) and E3 ubiquitin ligase (zinc finger domain) activities, enabling it to simultaneously remove activating ubiquitin chains from RIP1 and attach inhibitory chains to TRAF6, shutting down NF-κB signaling through two independent enzymatic steps. When A20 regulatory function is perturbed in skin tissue, NF-κB-driven cytokine production persists, promoting the Th17/IL-23 inflammatory axis characteristic of psoriasis rather than the anti-citrullinated protein antibody-driven response typical of RA.

The Evidence

The Nair et al. 2009 genome-wide scan⁴⁴ Nair et al. 2009 genome-wide scan
Published in Nature Genetics, February 2009 identified rs610604 as the lead TNFAIP3 signal for psoriasis (P=9×10⁻¹², OR=1.19), confirming TNFAIP3 alongside TNIP1 as the NF-κB pathway susceptibility locus for psoriasis. Both genes act downstream of TNF-α in the same negative-feedback loop, explaining why psoriasis — a disease driven by TNF-α and NF-κB activity in skin — is sensitive to genetic variation at this locus.

A meta-analysis of 13 case-control studies⁵⁵ meta-analysis of 13 case-control studies
13,908 psoriasis cases and 20,051 controls across European, Asian (Chinese, Indian, Pakistani), African (Egyptian), and American cohorts confirmed the association: G vs T OR=1.19 (95% CI 1.09–1.31, P=0.0002). The association holds across ancestry groups, though the G allele frequency varies substantially — common in African populations (~63%), intermediate in European (~33%) and South Asian (~32%) populations, and rare in East Asians (~8%). This pattern means the locus contributes differentially to psoriasis risk burden across populations.

A key insight from meta-analysis of the TNFAIP3 region in five European psoriasis cohorts⁶⁶ meta-analysis of the TNFAIP3 region in five European psoriasis cohorts
4,704 cases and 7,805 controls from UK, Swedish, and other European ancestry cohorts is that the psoriasis risk haplotype is categorically distinct from the autoimmune haplotypes associated with RA, SLE, and systemic sclerosis at the same locus. Haplotypes that are risk-conferring in SLE are actually protective in psoriasis, and vice versa. This means carrying the rs6920220 A allele (RA/SLE risk) does not compound psoriasis risk from rs610604 — these are independent signals marking different disease pathways through the same gene.

Practical Actions

The G allele at rs610604 confers modest but replicated psoriasis susceptibility (OR ~1.19 per allele). For GT and GG carriers who have or develop psoriasis, the most clinically actionable finding is the TNF inhibitor response prediction⁷⁷ TNF inhibitor response prediction
Michigan cohort of 432 psoriasis patients: GG genotype had 90.7% good response to etanercept vs 70.3% for TT; meta-analysis OR=1.64 for etanercept, OR=1.50 for all TNF blockers combined. G allele carriers are substantially more likely to respond well to etanercept and other TNF inhibitors — information worth sharing with a dermatologist before biologic selection.

For carriers without active psoriasis, the variant indicates modestly elevated NF-κB inflammatory tone in skin. Minimizing known psoriasis triggers — Koebner phenomenon (skin trauma), streptococcal infections, rapid withdrawal of systemic corticosteroids, certain medications (lithium, beta-blockers, antimalarials) — is particularly relevant. Maintaining serum 25(OH)D above 40 ng/mL supports skin barrier function and immune regulation; the VITAL trial⁸⁸ the VITAL trial
25,871 participants; vitamin D 2,000 IU/day reduced incident autoimmune disease by 22% (HR 0.78, P=0.05) provides the strongest randomized evidence for vitamin D's anti-inflammatory benefit in autoimmune-susceptible individuals.

Interactions

rs610604 tags a psoriasis-specific haplotype that is genetically and functionally distinct from the other TNFAIP3 variants in this database. The RA and SLE risk signals — rs6920220 (upstream regulatory, reduces A20 expression) and rs2230926 (F127C missense, impairs A20 enzymatic activity) — operate through different mechanisms and their risk haplotypes are not concordant with the psoriasis haplotype. Carrying risk alleles at both rs6920220 and rs610604 does not represent straightforward compound risk; the two signals may actually tag opposing haplotypes.

TNIP1 (encoded by TNIP1, also called ABIN-1) works directly with A20 in the same NF-κB feedback pathway: A20 recruits TNIP1 as a scaffolding partner to terminate NF-κB signaling. The TNIP1 variant rs17728338 is also a psoriasis susceptibility SNP — identified in the same Nair 2009 GWAS — and rs610604 G carriers who also carry the rs17728338 risk allele may face compounded psoriasis risk through dual impairment of the A20-TNIP1 complex.

The IL23A locus variant rs2066808 represents the parallel IL-23 pathway susceptibility in psoriasis. Both the NF-κB pathway (TNFAIP3/TNIP1) and the IL-23 signaling axis (IL23A/IL23R/IL12B) converge on Th17 cell activation in psoriatic skin lesions.